生命科学资讯

FDA Grants RMAT Designation to iRegene’s NouvNeu001, Cementing its Lead as the World’s First iPSC Therapy with Both FTD and RMAT Recognitions

AstraZeneca pens $630M pact to secure remaining rights to armored CAR-T from AbelZeta

Immunology biotech Agomab, eye-focused SpyGlass are latest biotechs to share IPO ambitions

Vedanta ‘significantly’ reduces headcount to fund lead bacteria cocktail program

Single-drug Exelixis aims to be top 5 solid tumor company in the US: CEO

Chutes & Ladders—RFK Jr. continues overhaul of CDC vaccine panel

ImmunityBio touts 15-month complete response in off-the-shelf CAR-NK trial

JPM26: Chugai chases new science and name recognition from US biopharma industry

JPM26: Astellas CEO resists 'rescue BD' as $6B Xtandi patent cliff nears

Boston Scientific to snap up thrombectomy specialist Penumbra in deal valued at $14.5B

Ocugen posts midphase gene therapy data, charting course for rivalry with Apellis, Astellas

Novo Nordisk Foundation invests $860M in Danish institute nurturing homegrown biotechs

All the meetings, none of the megadeals: Is JPM's purpose evolving?

Italy's Alfasigma pens €125M deal for injectable form of German biotech's HSV treatment

Charles River inks $510M deal to bring primate supply in-house

JPM26: With pricing deal in the books, Sanofi steels against lingering policy unknowns

JPM26: Leo Pharma, hungry for more partnerships, looks to widen reach in rare dermatology diseases

JPM26: Illumina working with China on 'a path through' its export troubles, sees academic research environment 'muted' for '26

Caldera launches with $112M, former Morphic CEO and IBD drug from China

JPM26, Day 3: Hundreds attend Biotech CEO Sisterhood meetup